This study was the first to systematically explore the associations of methylation of BIN1 promoter in peripheral blood with preclinical AD susceptibility and early pathological changes of CSF AD core biomarkers in a large cohort of participants without objective cognitive impairment. Here, BIN1 is linked to Cognitive impairment.